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Cocaine abuse has long been known to cause morbidity andmortality due to its cardiovascular toxic effects. The pathogenesis of the
cardiovascular toxicity of cocaine use has been largely reviewed, and the most recent data indicate a fundamental role of oxidative
stress in cocaine-induced cardiovascular toxicity, indicating that mitochondrial dysfunction is involved in the mechanisms of
oxidative stress. The comprehension of the mechanisms involving mitochondrial dysfunction could help in selecting the most
appropriate mitochondria injury biological marker, such as superoxide dismutase-2 activity and glutathionylated hemoglobin.
The potential use of modulators of oxidative stress (mitoubiquinone, the short-chain quinone idebenone, and allopurinol) in the
treatment of cocaine cardiotoxic effects is also suggested to promote further investigations on these potential mitochondria-
targeted antioxidant strategies.
1. Introduction
Cocaine (COC) use has long been known to cause morbidity
and mortality due to its cardiovascular toxic effects [1, 2].
COC can induce coronary and systemic vasoconstriction
and arrhythmias, such as atrial and ventricular fibrillation
[3], contraction band necrosis, atherosclerosis, and chest
pain [4] as well as acute myocardial infarction [5], up to
weeks after last consumption [6], even in presence of normal
coronary arteries [7].
The pathogenesis of cardiovascular toxicity related to
COC use has been reviewed recently [8–10]. Direct (block
of voltage-dependent K+ and Na++ channels) and indirect
(actions of catecholamines and their oxidation products on
α- and β-adrenergic receptors) are suspected to be the
primary pathogenic mechanisms.
The fundamental role of oxidative stress (OS) in COC-
induced cardiovascular toxicity is well established [8, 11].
Moreover, formation and accumulation of reactive oxygen
species (ROS) as a consequence of α- and β-adrenergic
receptors stimulation [12, 13], as well as of enzymatic or non-
enzymatic catabolism of catecholamines [14, 15], have been
demonstrated in cardiac and vascular cells. Mitochondrial
dysfunction leading to the production of ROS is implicated
in cardiovascular toxicity [16, 17]. Furthermore, a number
of drugs (e.g., anticancer drugs, antiviral drugs, oral antidia-
betic drugs, and recreational drugs) have been demonstrated
to induce toxic effects as a consequence of mitochondrial
dysfunctions [18]. An important contribution of mitochon-
dria in COC-induced OS and ROS production has been
shown in experimental in vivo models [19, 20] and in the
culture of rat cardiomyocytes [21]. In cardiomyocytes, the
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mitochondria themselves could become the target of COC-
induced OS, due to ROS accumulation.
A better understanding of the role of mitochondrial dys-
function in COC-induced cardiovascular toxicity will help to
select the most appropriate biological markers and to
develop novel mitochondria-targeted antioxidant strategies.
The purpose of the present paper is to review the state-of-
the-art study of mitochondrial involvement in ROS produc-
tion associated to COC-induced cardiovascular toxicity. In
particular, we focused on the identification of possible bio-
logical markers of OS and the possible beneficial effects of
OS modulators.
2. Mitochondrial Toxicity and Molecular
Targets
The molecular mechanisms by which drugs of abuse, COC
particularly, attack tissues’ integrity is an issue of paramount
importance. Pioneering experiments carried out using epithe-
lial cell cultures [22] or animal models, such as mice [23, 24],
have clearly suggested an involvement of mitochondrial
chemistry based on the impairment of the respiratory chain
with the rise of cytotoxic (ROS) species.
2.1. Mitochondrial Energy Production and Electron Transport
Chain. In cells, most of the ATP is synthesized by the mito-
chondria via a proton electrochemical potential gradient,
ΔμH+ [25]. Under physiological conditions, the mitochon-
dria are maintained operative by a resident mitochondrial
DNA in synergy with nuclear DNA, both regulating fusion
and fission and mitophagy dynamics of the organelles [26]
and, indeed, the expression and activity of the respiratory
chain electron transfer (eT) complexes. These complexes,
at the level of the inner mitochondrial membrane, either
collide among themselves randomly [27], the hypothesis
later on reconsidered by [28], or are organised in supramo-
lecular structures of the individual complexes [29]. Relevant
to cell bioenergetics, the structural stability of the supercom-
plexes and the functional performance of the respiratory
chain both have been shown to be modulated by the
mitochondrial membrane potential [30] and the protein
complexes phosphorylation. In addition and possibly related
to the cocaine-dependent chemistry involving the proteo-
membrane complexes, the functional performance of the
supercomplexes has been shown to strongly depend on the
membrane lipid composition and lipid peroxidation [31].
Regardless of whether organised as individual entities or as
supercomplexes, the respiratory chain components enable
the redox chemistry and the H+ translocation across the inner
mitochondrial membrane to occur, ensuring the built up and
maintenance of the proton-electrochemical gradient used by
the mitochondrial ATPase to synthesize the ATP [25, 32].
Relevant to the COC-induced chemistry, the mitochon-
drial function appears affected both directly, particularly at
the level of complex I [33], and indirectly, due to production
of reactive oxygen and nitrogen species (ROS and RNS), both
strongly affecting mitochondrial complex IV and permeabil-
ity and fluidity of the membranes. The mitochondrial ATP
synthesis depends on the cell metabolism, and the functional
status of the molecular machinery is modulated at several
levels, principally by the energetic demand and by the sub-
strates availability; in this context, Ca2+ plays a crucial role.
2.2. Mitochondria and Ca2+ Homeostasis. In the frame of the
molecular changes induced by COC, it is worth to recall its
interference with the cell integrated Ca2+ signaling and
homeostasis, whose network although intensively studied is
still only partly understood [34]. A complex set of equilibria
and chemical reactions tightly controls the flux of Ca2+
within all cell organelles and among specific molecular
components of the extracellular and the intracellular cell
compartments [34–37].
In the extracellular space, Ca2+ concentration is in the
mM range, whereas in the cytoplasm of a resting cell is
~102 nM [38]. The large concentration gradient is main-
tained by a dynamic equilibrium, involving a finely inte-
grated Ca2+ controlling molecular machinery [34, 39]
including a variety of plasma membrane Ca2+ channels,
receptors, exchangers, pumps, binding proteins, chaperons,
and transporters (Figure 1).
In the cell, the intracellular Ca2+ ions are accumulated
into specific cell compartments, the so-called Ca2+ stores.
These are the endoplasmic/sarcoplasmic reticulum (ER, for
simplicity), the mitochondria, and to some extent the Golgi
apparatus, together with the cell nucleus and other organ-
elles, such as the lysosomes and peroxisomes. The Ca2+
concentration in the stores may rise up to 1 or 2 orders of
magnitude (1–10μM) higher than that in the cytoplasm,
the value depending on the actual cell compartment, and its
functional state [40–42].
The mitochondria and ER are responsible for the
accumulation in the stores of most Ca2+ contributing, respec-
tively, to microcompartmentalization of up to 25% and 75%
Ca2+. These compartments are tightly interconnected at spe-
cialised sites named mitochondrial-associated membranes
(MAM). At this level, the side-by-side proximity between
ER and the mitochondria allows the transfer of Ca2+ ions to
the mitochondria from proteins and chaperons of the ER.
This process occurs via specific channels such as the
inositol-tri-phosphate receptors and the ryanodine receptors.
At the level of the outer mitochondrial membrane (OMM),
Ca2+ ions are transported from the cytoplasm into the inter-
membrane space (IMS) through the voltage-dependent
anion channel (VDAC): this reaction uses ATP; thus, once
promoted, ATP synthesis is stimulated. The transport, across
the inner membrane of Ca++ from the IMS to the mitochon-
drial matrix, is mainly contributed by the mitochondrial
calcium uniporter (MCU), an ion channel that selectively
drives the Ca2+ entry into the matrix. Transport occurs in
synergy with two complexes named the mitochondrial Ca2+
uptake 1 (MICU1) and the mitochondrial Ca2+ uptake 2
(MICU2), together setting the threshold for the Ca2+ unipor-
ter activity, also mediated by the essential MCU regulator
(EMRE) [43]. It is worthy to point out that the mitochondrial
Ca2+ loading and its back release to ER take part in the phys-
iological, vital ion-buffering system, while the mitochondrial
Ca2+ overloading most often paves the way to apoptosis or
even to cell irreversible damage.
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Uncontrolled mitochondrial Ca2+ accumulation rapidly
induces, in fact, a decrease of the mitochondrial membrane
potential (ΔΨ) leading to pathological production of ROS,
RNS with opening of the mitochondrial permeability transi-
tion pore (MPTP), and release of cytochrome c and other
proapoptotic components. The Ca2+ extrusion into the extra-
cellular compartment, therefore, is also under tight control: it
occurs via (i) the plasma membrane-associated Ca2+ ATPase
pump (PMCA), extruding against an unfavourable electro-
chemical gradient, 1 Ca2+ ion per hydrolysed ATP and (ii)
the potassium-independent Na+/Ca2++ exchanger (NCX)
and the potassium-dependent exchanger (NCKX) [44].
According to recent reports [45, 46], COC interferes with
the intracellular Ca2+ distribution and trafficking. The
interference has been proposed to occur at the level of the
store-operated calcium entry (SOCE) system and particularly
at the sigma-1 receptor site (Sig-1R) [47]. This is an intracel-
lular chaperone embedded in the endoplasmic reticulum and
is responsible for Ca2+ loading into the intracellular stores,
the mitochondria included. The functional activity of Sig-
1R was shown to be depressed by COC with impairment of
the Ca2+ equilibrium among the cell cytoplasm and stores
[40, 48]. It is worth noticing that the inhibition of SOCE
via COC binding at the Sig-1R [45], if confirmed, might lead
to even opposite pathophysiological effects. Depending on
the extent of binding and duration of SOCE inhibition, the
electrophoretic transfer of the positively charged Ca2+ in
the mitochondrial matrix could, initially, lead to a slight
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Figure 1: Main players of the cell Ca2+ molecular machinery as putative cocaine targets. Ideal intracellular Ca2+ concentration is maintained
through complex equilibria among the extracellular space (1mM), the cytoplasm (0.1μM), and the cellular stores (1.0–10 μM), such as the
mitochondrion, the endoplasmic reticulum (ER), the Golgi apparatus, and nucleus. The ion trafficking occurs via a variety of selective
membrane channels, Ca2+-binding proteins and transporters and ion exchangers and receptors, altogether responsible for Ca2+ import,
export, and homeostasis. Import occurs at the level of (i) cell plasma membrane through the calcium release-activated Ca2+ channel
protein 1 (ORAI1), the store-operated calcium entry channels (SOCE), and specific receptor-operated channels (ROC) such as AMPA,
NMDA, TRPC, and the voltage-dependent calcium channels (VDCC); (ii) endoplasmic reticulum (ER) through the sarco/endoplasmic
reticulum calcium ATPase (SERCA); (iii) mitochondria intermembrane space through the voltage-dependent anion channel (VDAC); and
(v) in the matrix by the mitochondrial uniporter (MCU), in synergy with the mitochondrial calcium uptake (MICU) system. Extrusion
occurs at the level of (i) cell plasma membrane mainly by the plasma membrane calcium ATPase (PMCA) and the sodium calcium
exchangers (NCX) also potassium-dependent (NCKX) and (ii) the ER by the ryanodine (RYR) and the inositol 1,4,5-trisphosphate
receptors (I P3R), as well as by the mitochondrial permeability transition pore (MPTP).
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depression of the mitochondrial ΔΨ, counterbalanced by
stimulation of ATP synthesis. No wonder, therefore, the
COC induced mitochondrial Ca2+ loading might be over-
looked. On the opposite, the persistence of the mitochondrial
Ca2+ loading leads to the opening of the MPTP and triggers
the apoptotic programme, with release of cytochrome c and
other proapoptotic components [34, 37, 49–52]. Accord-
ingly, COC-treated rat astroglioma cells had shown a dose-
dependent manner depression of mitochondrial ΔΨ and a
disruption of cell morphology [53].
2.3. Mitochondria, ROS, and RNS Production in the
Pathogenesis of Cardiovascular Toxicity. Cardiomyocytes
undergo incessant contractions, their mitochondria requir-
ing a regular supply of O2 and reducing substrates. Normally,
during mitochondrial respiration, the vast majority of O2 is
reduced to water via the electron transfer (eT) chain (4e−/O
atom), and only a small oxygen amount (0.1–2%) undergoes
a 1- or 2-electron reduction, with formation of highly reac-
tive partially reduced species, among which H2O2 and the
superoxide radical ion (O2
−·) are the best representatives.
These, when produced at sub-μmolar, nanomolar levels con-
tribute to the formation of the cellular pool of physiological
ROS that plays crucial signaling roles in a variety of condi-
tions. Similarly, under normal conditions, also a number of
more or less stable nitrogen oxides can be detected in the cells
and tissues (RNS). These include nitric oxide (NO) and
peroxynitrite (ONOO−), that is, highly reactive species
responsible, particularly the latter, for cell redox reactions
that are often highly detrimental, such as protein nitrosation
and membrane nitration. Among them, NO is present in the
environment at up to nanomolar concentrations, as
produced by the cell constitutive NOSs (eNOS and nNOS).
When present in large excess by the inducible iNOS
(≥μM), NO is a potent inhibitor of the mitochondrial
respiration [54]. Noticeably, in the presence of enough
O2 (5 ÷ 20 μM) and a suitable electron flux through the
respiratory chain sustained by the mitochondrial substrates
and reduced cytochrome c, the presence of nanomolar NO
does not depress (significantly) cell respiration. Interestingly,
from the bioenergetics signaling point of view, under these
conditions, the apparent affinity forO2 (KM, O2) of cytochrome
c oxidase (CcOX) rises [55], and the mitochondria become
sensitive to the O2 concentration, thus ready to shift to glyco-
lytic production of ATP [56, 57]. Under persistent hypoxic
conditions, when the mitochondrial respiratory chain
experiences for longer times a too low (insufficient) O2
concentration, a different landscape could be depicted. The
rapid activation of constitutive NOS is observed together with
the rise of NO concentration, whose increase, however,
induces a depression to the oxidative phosphorylation due
to, particularly, the inhibition of not only complex IV but also
to some extent of complex I [57]. As observed in neurons,
glycolysis takes place to compensate for the decreased ATP
synthesis, a finding not directly shown, however, in cardio-
myocytes. In addition, the cell environment turns acidic
facilitating the conversion of nitrite (NO2
−) into nitric oxide.
NO, in the presence of O2
−, at a diffusion-limited rate [58],
forms the highly cell detrimental peroxynitrite, ONOO−,
initiating and sustaining a vicious circle that leads to perma-
nent blockage of the mitochondrial eT [59, 60]. At this point,
the reactionmechanisms controlling the cell steady-state level
of ROS and RNSmight become severely insufficient.
In summary, due to complex I inhibition by COC, the
cardiomyocytes are likely called to face in rapid sequence,
though not necessarily in this chronological order, hypoxia
and cell acidification and rise of ROS/RNS species. As a
consequence, cell survival might be at risk and cell death
committed. Most frequently, the chemical species formed
are strong oxidizing agents such as hydrogen peroxide, hypo-
chlorous acid and peroxynitrite ion, and some of them are
radical, for example, the nitric oxide and superoxide anion
or the hydroxyl radical. Pathophysiologically relevant, not
only cardiomyocytes but also the endothelial cells and the
leucocytes, activated during the oxidative burst and the
inflammation response, are responsible for the environmen-
tal physicochemical change and the uncontrolled ROS and
RNS production. Altogether, the events point to excess
ROS/RNS as being responsible for the production of cell det-
rimental effects, thus linking together, at the mitochondrial
level, the OS, the early inflammation response, and cell death.
2.4. Crosstalk between the NO Chemistry and Cocaine. NO is
actively produced by the NOSs [61] or it is chemically gener-
ated all throughout our organism. Three NOS isoforms have
been identified and named after the cell tissues where they
were first detected: the endothelial NOS (eNOS) from the
endothelium, the neuronal NOS (nNOS) from the nervous
system, and the inducible NOS (iNOS) from immunocompe-
tent cells. These three isoforms share a substantial sequence
homology (50–60%) and some basic features such as one
catalytic Fe metal, the cofactors, and the substrates’ binding
sites. The expression and activity of the iNOS strongly
depend on cell stressors but are independent on cell pCa2+
whereas eNOS and nNOS, both constitutive enzymes, are
finely regulated by the concentration of cytosolic Ca2+. Rel-
evant to the NO chemistry, COC is known to react also with
the NMDA receptor [62], whose activation is induced via
Ca2+ rise, activity of nNOS, and NO production [63]
(Figure 2); a pathway was also reported for morphine [55].
NOSs use arginine and O2 as substrates. The affinity for
O2 is not equally distributed among the NOS isoforms. The
eNOS shows the highest affinity (KM~5μM), comparable to
that of the mitochondrial CcOX, while nNOS and iNOS have
a lower O2 affinity [57, 64].
Under hypoxic conditions, therefore, the O2 availability
can limit the enzymatic production of NO by the NOSs.
During hypoxia, maintenance of the NO homoeostasis may
require the release of NO from bulk nitrosothiols, or at the
expenses of metal ions (Fe2+ and Cu+) bound to proteins or
free in solution. These ions catalyze the reduction of nitrite
to NO and particularly at acidic pH and under hypoxic
conditions [65].
In agreement with previous reports [66–71], the involve-
ment of the NO chemistry in the development of COC addic-
tion has been recently confirmed by the results of the
selective 7-nitroindazole (7-N) inhibition of nNOS, induced
on Wistar rats. The animals when preliminarily treated with
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7-N showed a significant attenuation of the COC withdrawal
symptoms, and their brain-isolated synaptosomes displayed
both the reversal of the drug mitochondrial depression and
the decrease of GSH levels [72]. The fundamental role of
mitochondrial GSH in protecting membrane functions was
also observed in an experimental model of COC-induced
hepatotoxicity in rats [73].
In humans, PET measurements performed using C-11-
COC have shown in the early 90s that COC redistributes in
most organs and tissues although following different kinetics
(from seconds to several minutes) [74]. Redistribution likely
includes the skin, and heavy COC abusers often display
unpleasant skin signs, whose molecular mechanisms, how-
ever, are still mostly obscure. In this framework, it may be
worthy to recall that the systemic administration of COC to
male Sabra rats, thereafter subjected to skin biopsies, was able
to rise the iNOS and xanthine oxidase (XO) activity
prevented by specific inhibitors, such as the L-nitroso-
arginine methyl-ester (L-NAME) and the oxypurinol (OP),
respectively; the same authors reported similar results using
human keratinocytes in culture [75]. The proposition put
forward was that the oxidative-oxynitrosative damage was
bound to the skin accumulation of superoxide and nitric
oxide radicals, readily forming peroxynitrite [58] and
lipoperoxides, along with a marked decrease of ROS/RNS
scavengers such as reduced glutathione (GSH) and ascorbic
acid (AA) [75]. This hypothesis appears fully consistent with
the suggestion that the COC oxidative metabolites, and
among them particularly, the nitrogen N-derivatives, are
involved in the adverse biological effects observed in the
human body, at least when chronically exposed to COC [76].
3. Mitochondria and Cocaine-Induced
Cardiovascular Toxicity
As mentioned above, the role of mitochondria in the patho-
genesis of COC-induced cardiovascular toxicity is well recog-
nized [8, 20, 21, 33, 77]. COC may induce mitochondrial
dysfunction in cardiomyocytes and in endothelial cells, based
on direct and indirect mechanisms (Figure 3). Owing to its
pathophysiological relevance at both cardiomyocytes and
endothelial level, it may be worth to summarize the evidence
supporting the hypothesis that COC is likely responsible for a
specific mitochondrial impairment.
3.1. Cardiomyocytes. Notably, stimulation (and overstimula-
tion) of β-adrenergic receptors (β-AR) triggers the release of
Ca2+ in the mitochondria [78]. Indeed, stimulation of β-
adrenergic receptors increases Ca2+ levels in the cytosol,
through the activation of protein kinase A (PKA): increased
cytosolic Ca2+ leads in turn to phosphorylation of Ca2+-pro-
tein substrates and to the transfer ofCa
2+
into themitochondria
[79]. As mentioned above (Section 2.2), excess mitochondrial
Ca2+ impairs ATP production, causing nitro-oxidative stress
NOSc
Ca++
NO
Ca++
NMDAR
Ca++
Ca++
Cocaine
CcOX
Ca++
NO
NONO
Ca++
Figure 2: NMDA-receptor targeting by cocaine (hypothesis). The scheme is drawn by analogy to the functional effects observed at the level of
the cell nitric oxide chemistry and detected when treating glioma cells in culture with morphine [55]. It shows the activation of the cocaine-
mediated NMDA-R, leading to cytoplasmic Ca++ rise, activation of the constitutive NOS, and release of NO, targeting mitochondrial
respiratory chain complexes.
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with changes in permeability of the mitochondrial mem-
brane, altogether leading to structural degeneration of cardi-
omyocytes [9, 80, 81]. Overproduction of mitochondrial
ROS/RNS is in fact responsible for the massive opening of
MPTP [16, 82] resulting in a further dysfunctional and
structural degeneration of these organelles.
As already mentioned in Section 2.1 in isolated brain and
liver mitochondria [83] and in culture rat myocardial cells,
COC at high concentration had shown to inhibit complex I
(NADH dehydrogenase) activity [33] leading in turn to inhi-
bition of ATP synthesis. Accordingly, Fantel and colleagues
[84] demonstrated a COC inhibitory effect on mitochondria
respiration in rat embryo tissues. Importantly, in a model of
myocardial ischemia-reperfusion, it has been demonstrated
that a reduction in complex I activity may enhance ROS
production by complex III [85].
A further mitochondrial role in COC myocyte toxicity is
suggested by experimental studies, in which a mitochondria-
dependent apoptosis was observed [77, 86, 87]. Indeed, in
chronic COC-treated rats [77] and in cultured fetal [87]
and adult [86] myocytes, COC induced apoptosis. The cyto-
toxic effects on cardiomyocytes were related to the release of
cytochrome c from the mitochondria with activation of
caspase-9 and caspase-3, whose inhibition blocked cell
apoptosis [87]. Accordingly, a COC-induced apoptosis
associated with the release of cytochrome c was observed
also in cultured bovine coronary artery endothelial cells [88].
Interestingly, from the mechanistic point of view, in experi-
ments carried out using adult rat ventricular cardiac myo-
cytes, the caspase inhibition decreased the β-AR-stimulated
apoptosis [86].
Apoptosis activation was also observed in the cerebral
cortex of human COC addicts [89]. The postmortem brain
study showed a significant reduction in the content of mito-
chondrial cytochrome c in prefrontal cortex: the authors
suggest that the downregulation of cytochrome c could rep-
resent the induction of a counter regulatory adaptation to
brain apoptotic effects induced by COC via mitochondria
oxidative stress.
As mentioned above (Section 2.3), the accumulation of
ROS/RNS is an important event by which COC may induce
mitochondrial dysfunction with subsequent cardiotoxicity.
Although the extent of mitochondrial dysfunction produced
byCOC is still unknown, it is generally accepted that themito-
chondria are the main source of ROS production [90, 91]
meantime being targets of the oxidative stress.
High levels of circulating catecholamines
Mitochondrial abnormalities:
decrease of ATP production
Mitochondria-originated ROS production
Mitochondrial dysfunction and myocardial impairment 
Intramitochondrial Ca2+
overload
Inhibition of mitochondrial
electron transport chain
Indirect mechanismsDirect mechanism
Intracellular Ca2+
overload
Increased formation of
aminochromes
Increased NADPH 
oxidase/xanthine 
oxidase (O2–.)
Figure 3: Cocaine-induced mitochondrial dysfunction.
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COC-inducedROSproductionmayoccur bymechanisms
different from electron leak at the sites of the respiratory chain
complexes, namely, by
(i) formation of O2
−·, during catecolamine oxidation
(intramitochondria redox cycling),
(ii) synthesis of H2O2 by monoamine oxidase (MAO),
during oxidative deamination of catecholamines
(outer membrane of mitochondria),
(iii) ROS-induced ROS mitochondria formation [92].
Thus, ROS formation has been associated with COC-
induced catecholamine release [8, 93].
As noted, a crucial role in COC-induced toxicity is played
by transformation of catecholamines into aminochromes,
that is, the oxidative catecholamine metabolites [93]. Indeed,
when the level of catecholamines rises and the enzymes
responsible for their catabolism become less efficient, as it
might likely occur during COC abuse, catecholamines can
undergo oxidation [14, 94] with formation of aminochromes
(adrenochrome, dopachrome, and noradrenochrome); these
molecules are very active from the redox cycling point of
view. In bovine heart, it has been demonstrated that adreno-
chrome is reduced into semiquinone by mitochondrial
complex I [95] inducing in cardiomyocyte mitochondria
the formation of O2
−· [9, 94, 96].
Genova and coworkers [97] had shown that mitocondrial
complex I is involved both in initial generation of superoxide
and in the reduction of adrenochrome to its semiquinone
form. Furthermore, the superoxide anion O2
−· in turn
increases the adrenaline oxidation rate [14, 97]. Thus, the
mitochondria, on one side, are largely responsible for cardio-
myocyte oxidative stress, while on the other side, they are
themselves targets of the stress. In addition, it is worth
mentioning that the adrenochrome inhibits the oxidative
phosphorylation of cardiac mitochondria [98] and leads to
further enhancement of mitochondrial impairment.
Also MAO, flavin enzymes located in the outer
membrane of mitochondria, are responsible for oxidative
deamination of catecholamines, resulting in synthesis of
H2O2 leading in turn to highly reactive HO· [93, 99]. Accord-
ingly, in an experimental model in rats, it has been demon-
strated that myocardial oxidative stress could be partially
prevented by MAO inhibitors [100].
A further contribution to the stimulation ofCOC-induced
mitochondrial ROSproductionmay be derived fromNADPH
oxidase (Nox) and XO activity, also contributing to ROS gen-
eration in cardiac tissue [8, 13]. Indeed, the α1-adrenoceptor
stimulation increases the activation of Nox [13, 101] which
in turn produces O2
−·.
In an in vivo model of COC-induced diastolic dysfunc-
tion, it has been shown that 7 days of COC administration
induces an increase of mitochondrial ROS production in car-
diac fibers, with uncoupling of mitochondrial respiration
[20]. It is worth noticing that over a similar period of incuba-
tion COC administration induces also the activation of
Nox and XO, whose functional onset might precede mito-
chondrial failure [102]; this finding suggests that it is the
ROS production by the Nox and XO that first triggers the
ROS production by mitochondria not vice-versa [19].
Accordingly with this hypothesis, it has been suggested
that MitoQ [20] and allopurinol [19] treatments may prevent
oxidative stress and attenuate COC-induced cardiotoxicity.
3.2. Endothelial Cells. In endothelial cells, the mitochondrial
content is reduced, compared to other cell lines [103, 104].
Thus, by comparison with cardiac myocytes and other cell
types characterized by higher energy requirements, one
might expect, from the quantitative point of view (only), a
relatively smaller production by mitochondria of COC-
induced reactive species. This notwithstanding ROS produc-
tion by endothelial cell and their contribution to develop-
ment of heart disease [104] has been demonstrated in rat
[105] and in mouse [106] models. In cultured endothelial
cells used as experimental models of ischemia/reperfusion,
extensive amounts of ROS were observed [107].
The pro-oxidant activity of XO has been observed
[108], and XO from endothelial vasculature has been
proposed as the main ROS enzymatic source [93]; accord-
ingly, patients with ischemic cardiomyopathy oxypurinol-
induced inhibition of XO had shown improved myocardial
contractility [109]. In endothelial cells, the activity of XO
increases in I/R and it is a source of O2 when in the presence
of high levels of hypoxanthine.
4. Possible Biomarkers of Cocaine-Induced
Oxidative Stress
Notably, biological markers (biomarkers) may be useful to
quantify biological processes, disease state, or therapy predic-
tion and therapeutic tools [110, 111]. The increase in under-
standing mechanisms of oxidative stress in drug [8, 112, 113]
and alcohol [114, 115] addiction has led to identify oxidative
stressmarkers, that, although not validated and specific, could
help to evaluate oxidative status in drug abusers, both in acute
and chronic use and in withdrawal syndrome [116, 117]. In
Table 1, theproposedperipheral biomarkers ofOSand relative
references are listed.
In a recent study [117], it has been suggested that
thiobarbituric acid reactive substances (TBARS) and brain-
derived neurotrophic factor (BDNF) could be biomarkers
for evaluation of severity of crack COC use. Furthermore,
the authors found in male crack COC users a positive corre-
lation between TBARS levels and severity of abuse during
withdrawal syndrome. Notably, TBARS are an aspecific
biomarker of peripheral oxidative stress, consisting of a
quantification method for malondialdehyde (MDA) and sta-
bile product of lipid peroxidation [118, 119]. Accordingly
with clinical data, experimental studies in rats showed an
increase in MDA levels in the heart, both after COC self-
administration and extinction training [120] and after COC
injection [121, 122].
Conversely, in a clinical study aimed at evaluating total
antioxidant capacity in COC and methamphetamine sub-
jects [123], no difference was found in MDA blood levels
with respect to control. One possible explanation is that
discrepancy in results may be due to differences in some
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characteristics of participants. Indeed, Sordi and coworkers
[117] included subjects (N = 49) positive for current COC
use, while in the study from Walker and coworkers [123],
patients (N = 126) had used COC within 60 days prior to
the test and almost 23% were positive for use. It can be sug-
gested that the oxidative damage of lipids produced by cur-
rent COC use, counteracting by antioxidant defense (see
below), may shift towards antioxidant systems when the
subjects became progressively abstinent.
Even though TBARS are neither specific nor quantitative
[119], given that MDA plasma levels showed an increase in
acute myocardial infarction [124, 125] and also in brain
illnesses such as Parkinson’s [126] and Alzheimer’s [127]
diseases, this biomarker may be useful to assess relative level
of lipid peroxidation in COC abusers.
An increase in BDNF levels among crack users with
respect to control subjects was also found [117, 128]. The
function of this peripheral brain injury biomarker in drug-
induced neuroadaptation is well known [129], and recent
clinical data in chronic schizophrenia patients [130] showed
that both BDNF and OS may be involved in the pathophysi-
ology of this disease, suggesting an interaction mechanism
between oxidative damage and neurotrophin dysfunction.
Further investigations implicating these two peripherally
measured biomarkers should contribute to understand the
relative implication and interaction of oxidative stress and
neurotrophic factors in disorders.
5. Antioxidant Defense System Biomarkers of
Cocaine Oxidative Stress
Blood peripheral biomarkers of antioxidant enzymes were
evaluated in a population of COC user [123], (N = 126;
18% abstinent for 1 month and more prior to the inclusion).
The results showed no differences in the activities of glutathi-
one peroxidase and catalase between COC user and control
subjects, whereas a significant reduction in the SOD activity
was observed in erythrocytes.
Accordingly, in a rat model of COC-induced heart injury,
Moritz and coworkers [122] had shown that COC long-term
administration caused a significant decrease in SOD activity;
a biphasic trend in SOD concentration in rat spleen was
observed after chronic COC administration in vivo [131]
since that, after an early peak, SOD was significantly depleted
24 hours after COC treatment.
Notably SOD are an ubiquitous family of enzymes
[132, 133] in which actually three distinct isoforms has been
identified in humans. SOD1 (Cu/ZnSOD) is the major
intracellular form of SOD, accounting for almost 80% of total
SOD protein and is localized to the outer mitochondrial
membrane, while SOD2 (MnSOD) is localized exclusively in
the mitochondrial matrix [134, 135] and is expressed in the
heart, lung, liver, and blood cells. SOD3 is the major SOD of
human extracellular matrix of different tissues, mainly
expressed in the lung and scarcely in the brain [136].
In the rat liver, SOD1/Cu, Zn was found in the mitochon-
drial intermembrane space and SOD2 was found in the
matrix and also in the inner membrane [137]. Recent exper-
imental data in rats [120] indicate no changes in SOD activity
(irrespective of the isozyme subclass) in peripheral organs
such as the heart and the liver, both during COC self-
administration and during extinction phase (10 days).
Conversely, a significant enhancement in SOD activity was
found in the hippocampus and in the kidney. The authors
suggest that different changes in the activity of SOD in rat
brain structures and peripheral tissues may reflect differences
in OS status and that increases in the SOD enzymatic activity
could correspond to a reduction in MDA concentrations.
Due to its exclusive nuclear-encoded localization in the
mitochondrial matrix, SOD2 is considered the main
mitochondria antioxidant defense against toxic effects of
ROS. So it can be suggested that evaluation of activity of
SOD with respect to its isozyme subclasses could be a more
specific biomarkers of mitochondrial oxidative stress. A fur-
ther attention to different isozyme overexpression in specific
cell types and tissues may achieve a contribution to better
identify specific targets of oxidative stress.
Another peripheral biological marker that might reflect
oxidative status in tissues is the level of glutathionylatedhemo-
globin (Hb). The role of themechanismof S-glutathionylation
(i.e., theconjugationof glutathione toprotein cysteine residues
catalyzed by glutathione S-transferase P) in response to
oxidative stress in drug addiction was discussed in a recent
review [113]. Protein S-glutathionylation can be considered
a protective mechanism associated with elevated oxidative
stress in alcohol, heroin, and also in COC abuse. In preclin-
ical studies, acute and chronic COC treatment, but not
withdrawal, had shown to increase brain formation of
glutathionylated protein and a decrease in expression of
GSH-S-transferase P [138, 139]. Notably most of the glu-
tathionylated proteins are intracellular [110]; to date, in
human, the extent of glutathionylation in some pathologies
(i.e., diabetes mellitus, hyperlipidemia, and uremia) can be
measured only in blood [140], since in red blood cells Hb
accounts for 97% of protein composition [141]. Importantly,
increased levels of glutathionylated Hb were observed in
Table 1: Peripheral biomarkers of cocaine-induced oxidative stress.
Markers Sample Note References
MDA Plasma Aspecific biomarker of lipid peroxidation [117, 120–123]
TBARS Plasma Aspecific biomarker of lipid peroxidation [117, 128]
BDNF Plasma Negative correlation with severity of cocaine use [117, 128]
Glutathionylated Hb Plasma (RBC) Increased levels in oxidative stress conditions (i.e., cigarette smokers) [113, 140]
SOD Plasma (RBC) Decreased levels of activity [120–122, 131]
BDNF: malodialdehyde; TBARS: thiobarbituric acid reactive substances; BDNF: brain-derived neurotrophic factor; Hb: hemoglobin; RBC: red blood cells;
SOD: superoxide dismutase.
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cigarette smokers [142, 143] suggesting that its quantifica-
tion can be used as a low-invasive clinical biomarker of
oxidative stress-associated diseases. To our best of knowl-
edge, no clinical data are present in literature regarding
glutathionylated Hb in COC addicts.
In conclusion, we further retain that in studies concern-
ing the evaluation of oxidative stress in drug abuse and
clinical relevance of relative biomarkers it is important to
take into account factors that could significantly influence
both oxidative state and antioxidant defense. Physiological
(e.g., age, gender, body weight, diet, and lifestyle) and patho-
logic factors (psychiatric comorbidity, cardiovascular and
metabolic illnesses and their relative severity, etc.) as well as
drug abuse history [age of onset, duration, polydrug abuse,
tobacco smoking, alcohol use, and prevalence of current use
(i.e., during last month)] could affect total oxidative state.
Only early patient stratification based on their profile could
help to identify the most appropriate panels of both diagnos-
tic and prognostic biomarkers and conduct to optimal
management for the patients.
6. Modulators of Oxidative Stress in
Mitochondrial Protection: Future Direction
The use of antioxidants as therapeutic tools is still controver-
sial [8, 144, 145]. In a recent review on potential use of
modulators of OS in treatment of COC cardiotoxic effects,
Graziani and coworkers [8] underlies that both preclinical
and clinical data in literature has not yet been adduced to
argue conclusive evidence.
However, the fundamental role of mitochondria in COC-
induced OS strongly suggests that mitochondria-targeted
intervention could become a pharmacological strategy to
prevent and to treat this kind of damage. In Table 2, selective
antioxidant compounds for potential therapeutic use in COC
toxicity are reported.
In an experimental model of COC-induced cardiac dys-
function, MitoQ (mitoubiquinone) had shown to limit
COC-induced left ventricular dysfunction [20]. Accordingly,
in vitro studies [146, 147] of rat-stretched cardiomyocytes
showed that MitoQ could prevent both mitochondrial dam-
age and increase in XO activity and protect mitochondrial
membrane potential. MitoQ is actually the most studied
mitochondria-targeted antioxidant therapeutic compound
[148] and some human studies have confirmed its efficacy
in some cardiovascular pathologies, such as hypertension,
and drug toxicity (alcohol, adriamycin) [47]. To our best of
knowledge, no human studies are present in literature on
the potential effects of MitoQ in treatment of COC-induced
mitochondria toxicity.
On the basis of the abovementioned mechanisms of
mitochondria dysfunction induced by COC, other therapeu-
tic tools may be hypothesized.
The short-chain quinone idebenone has been also sug-
gested to be beneficial in mitochondrial dysfunction [149]
due to its antioxidant effects [150]. Idebenone proved to res-
cue ATP levels under conditions of impaired complex I
transferring electron in mitochondrial respiratory chain from
complex III [151]. The COC toxic effect of inhibition of the
activity of mitochondrial complex I [33] may be reversed
by some short-chain quinones. Consistent with this capacity
of ATP activity rescue, idebenone should be investigated
as a possible treatment for COC-induced dysfunction in
mitochondrial respiratory chain [152].
In an experimental model of COC-induced diastolic
dysfunction, XO activity inhibition by allopurinol [19] had
preserved both left ventricular systolic and the decrease in
ATP production, confirming the contribution of COC-
induced mitochondrial ROS production in cardiac tissue.
The protective role of allopurinol was confirmed in human
and rat left ventricular (LV) myocytes with volume overload
where the increase in ATP demand and the concurrent XO-
mediated ROS can decrease mitochondrial respiration and
contractile function [153] and in remodeling processes after
experimental myocardial infarction [154]. To date, some
clinical data appear to suggest that pharmacological XO
inhibition could represent potential tools for the treatment
of human cardiomyopathy [155]. The safety profile of
(the old) allopurinol underlies the possibility of testing this
XO inhibitor for further therapeutic interventions.
7. Conclusion
In the present paper, the role of cardiovascular mitochondria
in COC-induced OS and ROS production was reported.
Preclinical and clinical data underlie the fundamental partic-
ipation of mitochondrial dysfunction to pathogenesis of
COC-induced cardiovascular toxicity. As a consequence,
possible biological peripheral markers of OS mitochondrial
injury may be proposed. Both the antioxidant defense system
biomarkers SOD2/MnSOD and glutathionylated Hb appear
to be appropriate peripheral biomarkers of oxidative stress:
since clinical data in COC and psychotropic drug users are
inadequate to draw any conclusion, it could suggest that
additional studies in this population subjects may be
performed. Even in the case of potential therapeutic effects
of mitochondrial protection, further studies on the proposed
antioxidant drugs (MitoQ, idebenone, and allopurinol) will
be crucial to assess their effectiveness or inability to counter-
act mitochondrial dysfunctions induced by cocaine.
Table 2: Potential therapeutic use of selective antioxidant
compounds for cocaine-induced mitochondrial impairment.
Antioxidant
compounds
Mechanism of action References
MitoQ
Inhibition of XO activity
and protection of mitochondria
membrane potential
[20, 47, 148]
Idebenone
(short chain
quinone)
Transferring of electron in
mitochondrial respiratory
chain from cytoplasm to
complex III (bypass deficiency
in complex I)
[149–152]
Allopurinol
Inhibition of XO activity
and consequent rescue of in
ATP production
[19, 153–155]
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Abbreviations
AA: Ascorbic acid
β-AR: β-Adrenergic receptors
BDNF: Brain-derived neurotrophic factor
CcOX: Cytochrome c oxidase
COC: Cocaine
ΔΨ: Mitochondrial membrane potential
eNOS: Endothelial NOS
ER: Endoplasmic/sarcoplasmic reticulum
eT: Electron transfer
GSH: Glutathione
Hb: Hemoglobin
H2O2: Hydrogen peroxide
HO·: Hydroxyl radical
HO: Heme oxygenase
iNOS: Inducible NOS
IMS: Intermembrane space
L-NAME: L-Nitroso-arginine methyl-ester
MAM: Mitochondrial-associated membranes
MAO: Monoamine oxidase
MDA: Malondialdehyde
MCU: Mitochondrial calcium uniporter
MICU1: Mitochondrial Ca2+ uptake 1
MICU2: Mitochondrial Ca2+ uptake 2
MitoQ: Mitoubiquinone
MPTP: Mitochondrial permeability transition pore
NAC: N-Acetylcysteine
nNOS: Neuronal NOS
NO·: Nitric oxide
Nox: NADPH oxidase
NMDA: N-Methyl-D-aspartate
NOS: NO synthase
O2
−·: Superoxide anion
OMM: Outer mitochondrial membrane
ONOO-: Peroxynitrite ion
OP: Oxypurinol
OS: Oxidative stress
OXPHOS: Oxidative phosphorylation
PKA: Protein kinase A
PMCA: Plasma membrane associated Ca2+ ATPase
pump
RNS: Reactive nitrogen species
ROS: Reactive oxygen species
Sig-1R: Sigma-1 receptor site
SOCE: Store-operated calcium entry
SOD: Superoxide dismutase
TBARS: Thiobarbituric acid reactive substances
XO: Xanthine oxidase
EMRE: Essential MCU regulator
VDAC: Voltage-dependent anion channel
NCX: Potassium-independent Na+/Ca2++ exchanger
NCKX: Potassium-dependent Na+/Ca2++ exchanger
7-N: 7-Nitroindazole.
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